General Information
Drug ID
DR00251
Drug Name
Docetaxel
Synonyms
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; ANX-514; Docetaxel (INN); Docetaxel 114977-28-5; Docetaxel anhydrous; Docetaxel, Trihydrate; EmDOC; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; N-debenzoyl-N-Boc-10-deacetyl taxol; RP-56976; SDP-014; TXL; Taxotere; Taxotere (TN); Taxotere(R); XRP-6976L
Drug Type
Small molecular drug
Indication Breast cancer [ICD11: 2C60-2C6Z] Approved [1]
Lung cancer [ICD11: 2C25] Approved [1]
Prostate cancer [ICD11: 2C82] Approved [1]
Gastric cancer [ICD11: 2B72] Approved [1]
Head and neck cancer [ICD11: 2B60-2B6E] Approved [1]
Ovarian cancer [ICD11: 2C73] Approved [1]
Therapeutic Class
Anticancer Agents
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=148124"></iframe>
3D MOL 2D MOL
Formula
C43H53NO14
Canonical SMILES
CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
InChI
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChIKey
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
CAS Number
CAS 114977-28-5
Pharmaceutical Properties Molecular Weight 807.89 Topological Polar Surface Area 224
Heavy Atom Count 58 Rotatable Bond Count 13
Hydrogen Bond Donor Count 5 Hydrogen Bond Acceptor Count 14
XLogP
1.6
PubChem CID
148124
PubChem SID
10249812 , 103172104 , 104418276 , 117664410 , 117682515 , 12014196 , 124950708 , 126606827 , 126630894 , 126657365 , 13410 , 134337881 , 136340291 , 136375539 , 14791415 , 14815974 , 17424977 , 24845209 , 26683886 , 46225079 , 46506766 , 494081 , 53790583 , 56310805 , 56310954 , 56311107 , 56311313 , 56311574 , 56312625 , 56312880 , 56312940 , 56312941 , 56313207 , 56313989 , 56314033 , 56314070 , 56314178 , 56314280 , 57346703 , 78743198 , 7890914 , 7979114 , 81044598 , 822539 , 833094 , 87678200 , 92308884 , 92711403 , 96024562 , 99319097
ChEBI ID
ChEBI:4672
TTD Drug ID
D0O5WP
DT(s) Transporting This Drug BCRP Transporter Info Breast cancer resistance protein Substrate [2]
MRP1 Transporter Info Multidrug resistance-associated protein 1 Substrate [3]
MRP2 Transporter Info Multidrug resistance-associated protein 2 Substrate [4]
MRP7 Transporter Info Multidrug resistance-associated protein 7 Substrate [5]
OATP1B1 Transporter Info Organic anion transporting polypeptide 1B1 Substrate [6]
OATP1B3 Transporter Info Organic anion transporting polypeptide 1B3 Substrate [7]
P-GP Transporter Info P-glycoprotein 1 Substrate [8]
TAPL Transporter Info TAP-like protein Substrate [9]
References
1 Docetaxel was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
3 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
4 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
5 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
6 FDA Drug Development and Drug Interactions
7 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
8 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
9 RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.